human coagulation factor X: clinical use

Prescribing considerations

• Initiate under a clinician experienced in rare bleeding disorders.
• Individualise treatment using clinical response and factor X activity rather than a fixed regimen.
• Record the product name and batch number for every administration.
• Standard pathogen-reduction measures reduce but cannot eliminate transmission risk from this plasma-derived product. Hepatitis A and B vaccination may be appropriate for regularly treated patients.
• Home therapy requires structured training and periodic review.

Contraindications and cautions

• Hypersensitivity to human coagulation factor X or any excipient.
• Avoid factor Xa inhibitors in patients with factor X deficiency; this product is not an antidote for direct oral anticoagulants in people without factor X deficiency.

Monitoring

• Clinical control of bleeding and serial factor X activity where appropriate
• Factor X levels around surgery
• Neutralising factor X inhibitors if recovery is inadequate or bleeding remains uncontrolled
• Clinical and laboratory assessment for thrombosis after suspected excessive administration

Clinical pharmacology

Plasma-derived factor X replaces endogenous factor X. Activation to factor Xa permits formation of the factor Xa–Va prothrombinase complex, generating thrombin and subsequently cross-linked fibrin.

Formulation and product differences

• The presentation contains 500 IU powder with 5 mL water for injections and a single-use Mix2Vial transfer device.
• After reconstitution, the concentration is approximately 100 IU/mL.
• It contains sucrose and sodium-containing excipients, must not be frozen and should be protected from light.

Injection

Route: Parenteral

Strengths: 250 units, 500 units